Abstract Number: 2489 • 2016 ACR/ARHP Annual Meeting
Joint Damage Appears As Severe As Inflammation According to Physician Visual Analog Scales in Patients with Rheumatoid Arthritis Regardless of Disease Severity at 2 Sites, Which May Limit Results of a Treat-to-Target Strategy
Background/Purpose: A physician estimate of global status (DOCGL) on a 0-10 visual analog scale (VAS) was developed initially to assess inflammation in patients with rheumatoid…Abstract Number: 2490 • 2016 ACR/ARHP Annual Meeting
Impact of Obesity Activity Indices and Therapeutic Dosage in Patients with Rheumatoid Arthritis in Dominican Republic
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic arthritis that mainly affects small and medium joints. It is the most common form…Abstract Number: 2491 • 2016 ACR/ARHP Annual Meeting
Is It Possible to Predict Which Patients Treated with Biologic Agents for Rheumatic Diseases Will Develop Anti-Drug Antibodies ?
Background/Purpose: All biologic agents (bDMARDs) currently used in rheumatology can induce anti-drug antibodies (ADAB), which will influence the drug levels and the drug effectiveness. Why…Abstract Number: 2492 • 2016 ACR/ARHP Annual Meeting
Mode of Administration in Rheumatoid Arthritis Treatments: An Exploration of Patient Preference for an ‘Ideal Treatment’
Background/Purpose: The high prevalence and significant burden of RA has led to the development of a wide variety of treatments; specifically, conventional synthetic DMARDs, and…Abstract Number: 2493 • 2016 ACR/ARHP Annual Meeting
Patient Characteristics and Medication Utilization Patterns of Infliximab-Treated Rheumatoid Arthritis Patients Subsequently Transitioned to Intravenous Golimumab
Background/Purpose: Infliximab (IFX) and golimumab (GLM-IV) for intravenous use are anti-TNF agents indicated for rheumatoid arthritis (RA) and differ in weight-based dose, induction schedule, and…Abstract Number: 2494 • 2016 ACR/ARHP Annual Meeting
The Effect of Body Mass on DAS28 Response in Patients with Rheumatoid Arthritis Treated with Abatacept
Background/Purpose: Abatacept is an effective biologic agent indicated for the treatment of RA.1 Recent studies have indicated that obesity and being overweight could reduce the…Abstract Number: 2495 • 2016 ACR/ARHP Annual Meeting
The Prevalence of Loss of Response to Treatment with a Tumor Necrosis Factor Inhibitor and/or Methotrexate in Patients with Rheumatoid Arthritis
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) who achieve disease control in response to treatment with a tumor necrosis factor inhibitor (TNFi) may lose that…Abstract Number: 2496 • 2016 ACR/ARHP Annual Meeting
DMARD, Biologic and Small Molecule Drug Use Among ACPA Positive and ACPA Negative RA Patients in a Tertiary Referral Center
Background/Purpose: Rheumatoid arthritis (RA) can be divided into two major subsets based on the presence or absence of antibodies to citrullinated peptide antigens (ACPA). Some…Abstract Number: 2497 • 2016 ACR/ARHP Annual Meeting
Associations Between Dietary Intake of Vitamin D, Omega-3 Fatty Acids, Folate and EULAR Response in Patients with Early Rheumatoid Arthritis
Background/Purpose: We hypothesized that increased dietary intake of vitamin D and omega-3 fatty acids (FA) prior to disease modifying anti-rheumatic drug (DMARD) initiation may associate…Abstract Number: 2498 • 2016 ACR/ARHP Annual Meeting
Tender Joints Is a Consistent Negative Predictor of Sustained Remission in Aggressively Treated Patients with Early Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) care has moved towards early diagnosis and treatment to improve long-term patient outcomes. Our objective was to assess prognostic factors for…Abstract Number: 2499 • 2016 ACR/ARHP Annual Meeting
Tocilizumab Achieves Rapid Reduction of Disease Activity and Has Beneficial Effects on Bone Mineral Density in Patients with Rheumatoid Arthritis
Tocilizumab achieves rapid reduction of disease activity and has beneficial effects on bone mineral density in patients with rheumatoid arthritis Maria Höhle, MD11Orthopedic, Medical, Rheumatologic…Abstract Number: 2500 • 2016 ACR/ARHP Annual Meeting
Prevalence of Sustained Remission in Patients with Rheumatoid Arthritis in Sweden. Impact of Criteria Sets and Early Treatment, a Nationwide Register Study in Sweden
Background/Purpose: The Swedish Society for Rheumatology guidelines recommend remission as treatment goal for patients with rheumatoid arthritis (RA). The Swedish quality registry (SRQ) is a…Abstract Number: 2501 • 2016 ACR/ARHP Annual Meeting
Radiographic Damage in Patients with RA Increases By 8.3% per Year Disease Duration, in the Era of Biologic Dmards. Results from the Scqm Cohort
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease leading to joint destructions, if untreated. Treatment with biologic DMARDs has shown to favourably influence disease…Abstract Number: 2502 • 2016 ACR/ARHP Annual Meeting
Tocilizumab Therapy Reduces Corrected QT Interval in Patients with Rheumatoid Arthritis without Cardiac Symptoms
Background/Purpose: Individuals with rheumatoid arthritis (RA) have a two-fold higher risk of sudden death than the healthy age- and sex-matched general population. Although the underlying…Abstract Number: 2503 • 2016 ACR/ARHP Annual Meeting
Making Room for RA Patient Symptoms into Treatment Decision: A Physician Perspective Study
Background/Purpose: Little is known on what subjective or objective data that rheumatologists consider most important for them to inform their treatment decisions for patients…
ACR Meeting Abstracts